Evidence map›Paper›PMID 28126904›Full record

ArticleThe Journal of biological chemistry2017

Biochemical and Cellular Analysis Reveals Ligand Binding Specificities, a Molecular Basis for Ligand Recognition, and Membrane Association-dependent Activities of Cripto-1 and Cryptic.

Senem Aykul, Anthony Parenti, Kit Yee Chu, Jake Reske, Monique Floer, Amy Ralston, Erik Martinez-Hackert

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Cripto-1 acts as a molecular bridge linking nodal to ALK4 via distinct structural domains.Protein science : a publication of the Protein Society · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Senem AykulFrom the Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, Michigan 48824-1319.
Anthony ParentiFrom the Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, Michigan 48824-1319.
Kit Yee ChuFrom the Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, Michigan 48824-1319.
Jake ReskeFrom the Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, Michigan 48824-1319.
Monique FloerFrom the Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, Michigan 48824-1319.
Amy RalstonFrom the Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, Michigan 48824-1319.
Erik Martinez-HackertFrom the Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, Michigan 48824-1319 emh@msu.edu.
Michigan State University · US

Funding

Molecular Regulation of Cell Fate in Stem Cells and Early Mouse EmbryosR01GM104009 · NIGMS · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI RALSTON, AMY · 2013 to 2018
$2.3M
Activin A antagonist for treatment of cancer-associated cachexiaR43CA203180 · NCI · ABREOS BIOSCIENCES, INC. · PI MESSMER, BRADLEY T · 2015 to 2015
$225k
Novel Activin A Antagonists for Treatment of OsteoporosisR41AR068804 · NIAMS · ABREOS BIOSCIENCES, INC. · PI MARTINEZ HACKERT, ERIK MATTHIAS, MESSMER, BRADLEY T · 2015 to 2015
$225k
NCI NIH HHS R43 CA203180NIAMS NIH HHS R41 AR068804NIGMS NIH HHS R01 GM104009
6 · The paper itself

Abstract

Transforming growth factor β (TGF-β) pathways are key determinants of cell fate in animals. Their basic mechanism of action is simple. However, to produce cell-specific responses, TGF-β pathways are heavily regulated by secondary factors, such as membrane-associated EGF-CFC family proteins. Cellular activities of EGF-CFC proteins have been described, but their molecular functions, including how the mammalian homologs Cripto-1 and Cryptic recognize and regulate TGF-β family ligands, are less clear. Here we use purified human Cripto-1 and mouse Cryptic produced in mammalian cells to show that these two EGF-CFC homologs have distinct, highly specific ligand binding activities. Cripto-1 interacts with BMP-4 in addition to its known partner Nodal, whereas Cryptic interacts only with Activin B. These interactions depend on the integrity of the protein, as truncated or deglycosylated Cripto-1 lacked BMP-4 binding activity. Significantly, Cripto-1 and Cryptic blocked binding of their cognate ligands to type I and type II TGF-β receptors, indicating that Cripto-1 and Cryptic contact ligands at their receptor interaction surfaces and, thus, that they could inhibit their ligands. Indeed, soluble Cripto-1 and Cryptic inhibited ligand signaling in various cell-based assays, including SMAD-mediated luciferase reporter gene expression, and differentiation of a multipotent stem cell line. But in agreement with previous work, the membrane bound form of Cripto-1 potentiated signaling, revealing a critical role of membrane association for its established cellular activity. Thus, our studies provide new insights into the mechanism of ligand recognition by this enigmatic family of membrane-anchored TGF-β family signaling regulators and link membrane association with their signal potentiating activities.

Indexed as

Amino Acid SequenceCell DifferentiationCell MembraneGPI-Linked ProteinsHep G2 CellsHumansIntercellular Signaling Peptides and ProteinsLigandsNeoplasm ProteinsProtein BindingProtein Serine-Threonine KinasesReceptors, Transforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type IISequence Homology, Amino AcidSignal TransductionTransforming Growth Factor betaCFC1 protein, humanGPI-Linked ProteinsIntercellular Signaling Peptides and ProteinsLigandsNeoplasm ProteinsProtein Serine-Threonine KinasesReceptors, Transforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type IITDGF1 protein, humanTransforming Growth Factor betaactivin A receptor, type I (ACVR1)bone morphogenetic protein (BMP)protein-protein interactionsignal transductionsurface plasmon resonance (SPR)transforming growth factor β (TGF-β)

Identifiers

PMID28126904
PMCPMC5354514
OpenAlexW2583064761

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.